- Home
- EQ vs STKS Comparison
EQ vs STKS Comparison
Compare EQ & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- STKS
- Stock Information
- Founded
- EQ 2017
- STKS 2004
- Country
- EQ United States
- STKS United States
- Employees
- EQ N/A
- STKS N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- STKS Restaurants
- Sector
- EQ Health Care
- STKS Consumer Discretionary
- Exchange
- EQ Nasdaq
- STKS Nasdaq
- Market Cap
- EQ 57.8M
- STKS 57.2M
- IPO Year
- EQ 2018
- STKS N/A
- Fundamental
- Price
- EQ $1.00
- STKS $1.90
- Analyst Decision
- EQ Hold
- STKS Hold
- Analyst Count
- EQ 1
- STKS 3
- Target Price
- EQ $1.00
- STKS $4.50
- AVG Volume (30 Days)
- EQ 395.1K
- STKS 76.4K
- Earning Date
- EQ 11-13-2025
- STKS 11-06-2025
- Dividend Yield
- EQ N/A
- STKS N/A
- EPS Growth
- EQ N/A
- STKS N/A
- EPS
- EQ N/A
- STKS N/A
- Revenue
- EQ $4,392,000.00
- STKS $820,588,000.00
- Revenue This Year
- EQ N/A
- STKS $26.58
- Revenue Next Year
- EQ N/A
- STKS $5.37
- P/E Ratio
- EQ N/A
- STKS N/A
- Revenue Growth
- EQ N/A
- STKS 51.57
- 52 Week Low
- EQ $0.27
- STKS $1.75
- 52 Week High
- EQ $2.35
- STKS $5.26
- Technical
- Relative Strength Index (RSI)
- EQ 39.57
- STKS 30.73
- Support Level
- EQ $0.98
- STKS $1.75
- Resistance Level
- EQ $1.16
- STKS $1.88
- Average True Range (ATR)
- EQ 0.14
- STKS 0.13
- MACD
- EQ -0.02
- STKS -0.01
- Stochastic Oscillator
- EQ 30.20
- STKS 11.62
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.